acamprosate sustained release sprinkles (SF 999) / Confluence Pharma, AOP Orphan Pharma - LARVOL DELTA

Adjunctive medical expulsive therapy with tamsulosin for repeated extracorporeal shock wave lithotripsy: a systematic review and meta-analysis. (PubMed, Int Braz J Urol) - "Adjunctive MET with tamsulosin is effective in patients with specific stone size or location that received repeated ESWL. However, no well-designed RCT that used computed tomography for the detection and assessment of residual stone fragments was found. More studies with high quality and the comparison between tamsulosin and secondary ESWL are needed in the future. Available at. https://www.intbrazjurol.com.br/pdf/aop/2020-0093RW.pdf."

Journal • Retrospective data • Review • Pain • Renal Calculi • Urolithiasis

Partial nephrectomy provides equivalent oncologic outcomes and better renal function preservation than radical nephrectomy for pathological T3a renal cell carcinoma: A meta-analysis. (PubMed, Int Braz J Urol) - "PN may be more suitable for treating pT3a RCC than RN because it provides a similar survival time (OS or RFS) and superior renal function. Nevertheless, this result is still disputed, and more high-quality studies are required. Available at. https://www.intbrazjurol.com.br/pdf/aop/2020-0167RW.pdf."

Journal • Retrospective data • Review

Confluence gets $200K from University-affiliated venture fund to develop fragile X treatment (Fragile X News Today) - "An Indiana University-affiliated venture fund has invested $200,000 in Confluence Pharmaceuticals to continue development of the company’s lead product for the treatment of fragile X syndrome....Based on the generic compound acamprosate...Capital from the Indiana University (IU) Philanthropic Venture Fund...will be used to speed up clinical development and regulatory activity of the investigational treatment."

Financing